News and Announcements
COMMENTARY
iMASSAGE: Programmable extracellular vesicle therapy for chronic gut disorders and beyond
Show Less
1
Faculty of Medicine and Health, Sydney School of Pharmacy, Sydney Nano Institute, The University of Sydney, Camperdown, New South Wales,
Australia
2
Institute of Translational Medicine, Shanghai University, Shanghai,
China
3
MedEng‐X Institutes, Shanghai University, Shanghai,
China
4
Organoid Research Centre, Shanghai University, Shanghai,
China
5
National Centre for Translational Medicine (Shanghai) SHU Branch, Shanghai University, Shanghai,
China
6
Suzhou Innovation Centre of Shanghai University, Suzhou, Jiangsu,
China
7
Sanming Second Hospital, Sanming, Fujian,
China
8
Division of Biomedical Engineering, Department of Materials Science and Engineering, Uppsala University, Uppsala,
Sweden
Submitted: 29 November 2025 | Revised: 16 March 2026 | Accepted: 30 March 2026 | Published: 26 May 2026
© 2026 by the Author(s). Licensee Biomaterials Translational, USA. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 (CC BY-NC-SA 4.0) (https://creativecommons.org/licenses/by-nc-sa/4.0/deed.en)
Funding
The authors acknowledge support from the Leo Foundation, Denmark, under award number LF-OC-25-002046 (WC), the Wenner-Gren Foundation, Sweden, under award number GFO2023-0008 (WC), and the National Health and Medical Research Council, Australia, under award number 2037119 (WC). The content is solely the authors’ responsibility and does not necessarily represent the official views of the organizations and funding agencies.
Conflict of interest
The authors declare no conflict of interest.
References
- Giles EM, D’Adamo GL, Forster SC. The future of faecal transplants. Nat Rev Microbiol. 2019;17(12):719. doi: 10.1038/s41579-019-0271-9
- Yelin I, Flett KB, Merakou C, et al. Genomic and epidemiological evidence of bacterial transmission from probiotic capsule to blood in ICU patients. Nat Med. 2019;25(11):1728-1732. doi: 10.1038/s41591-019-0626-9
- Ullah H, Arbab S, Chang C, et al. Gut microbiota therapy in gastrointestinal diseases. Front Cell Dev Biol. 2025;13:1514636. doi: 10.3389/fcell.2025.1514636
- Klyachko NL, Arzt CJ, Li SM, Gololobova OA, Batrakova EV. Extracellular vesicle-based therapeutics: Preclinical and clinical investigations. Pharmaceutics. 2020;12(12):1171. doi: 10.3390/pharmaceutics12121171
- Xie J, Li Q, Nie S. Bacterial extracellular vesicles: An emerging postbiotic. Trends Food Sci Technol. 2024;143:104275. doi: 10.1016/j.tifs.2023.104275
- Zhou X, Li W, Wang S, et al. YAP aggravates inflammatory bowel disease by regulating M1/M2 macrophage polarization and gut microbial homeostasis. Cell Rep. 2019;27(4):1176-1189.e5. doi: 10.1016/j.celrep.2019.03.028
- He T, Ma J, Liu S, et al. MicroRNA‐microbiota interactions: Emerging strategies for modulating intestinal homeostasis and enhancing host health. IMetaomics. 2025;2(1):e57. doi: 10.1002/imo2.57
- Shen Q, Huang Z, Ma L, et al. Extracellular vesicle miRNAs promote the intestinal microenvironment by interacting with microbes in colitis. Gut Microbes. 2022;14(1):2128604. doi: 10.1080/19490976.2022.2128604
- Wan S, Wang K, Huang P, et al. Mechanoelectronic stimulation of autologous extracellular vesicle biosynthesis implant for gut microbiota modulation. Nat Commun. 2024;15(1):3343. doi: 10.1038/s41467-024-47710-w
- Zhou J, Li M, Chen Q, et al. Programmable probiotics modulate inflammation and gut microbiota for inflammatory bowel disease treatment after effective oral delivery. Nat Commun. 2022;13(1):3432. doi: 10.1038/s41467-022-31171-0
- Zeng Y, Cui X, Li H, Wang Y, Cheng M, Zhang X. Extracellular vesicles originating from the mechanical microenvironment in the pathogenesis and applications for cardiovascular diseases. Regen Ther. 2024;26:1069-1077. doi: 10.1016/j.reth.2024.10.012
- Patel N, Avery E, Chung EJ. Supramolecular hydrogels for sustained extracellular vesicle delivery. MRS Commun. 2024;14(5):1037-1044. doi: 10.1557/s43579-024-00589-6
- Wang Y, Meng D, Shi X, et al. Injectable hydrogel with miR- 222-engineered extracellular vesicles ameliorates myocardial ischemic reperfusion injury via mechanotransduction. Cell Rep Med. 2025;6(3):101987. doi: 10.1016/j.xcrm.2025.101987
- Meng F, Deng Y, Li W, Zheng A, Lu M, Xing H. Engineered extracellular vesicles: From design strategies to therapeutic applications.Extracell Vesicle. 2026;7:100104. doi: 10.1016/j.vesic.2026.100104
- Chrzanowski W, Wolfram J. Rethinking extracellular vesicle signaling. Adv Mater. 2026;38(20):e22172. doi: 10.1002/adma.202522172
- Kojima R, Bojar D, Rizzi G, et al. Designer exosomes produced by implanted cells intracerebrally deliver therapeutic cargo for Parkinson’s disease treatment. Nat Commun. 2018;9(1):1305. doi: 10.1038/s41467-018-03733-8
- Rudge C, McClelland R, Chrzanowski W, Davis RL. The regulatory landscape for extracellular vesicle therapies: Australian context and future directions. Extracell Vesicles Circ Nucl Acids. 2026;7(1):292-301. doi: 10.20517/evcna.2025.129
